Amgen’s proposed acquisition of Otezla from Celgene for $13.4 billion provides 71 per cent to deal value
In August 2019, the healthcare industry reported 37 deals worth $18.9 billion as compared to the last 12-month average (August 2018 to July 2019) of 58 deals worth $27 billion. Amgen’s proposed acquisition of worldwide rights to Otezla (apremilast), an oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets and liabilities, from Celgene for $13.4 billion is one of the major deals with a contribution of 71 per cent to the total deal value
in August 2019. Permira Funds’ proposed acquisition of Cambrex, a small molecule company for $2.4 billion; and Vertex Pharmaceuticals announcing to acquire Semma Therapeutics, a biotechnology company, for a purchase consideration of $950 million are other notable acquisitions announced in August 2019.
The healthcare industry reported 72 venture capital (VC) deals worth $1.3 billion in August 2019, compared to the last 12-month average (August 2018 to July 2019) of 90 deals worth $1.8 billion. D&D Pharmatech raising $137.1 million in series B financing round; Juvenescence raising $100 million in series B financing round; Graybug Vision raising $80 million in series C
venture financing round; Oncorus raising $79.5 million in series B financing round are some of the major VC deals reported in August 2019.